Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0030863,
umls-concept:C0031381,
umls-concept:C0032305,
umls-concept:C0041044,
umls-concept:C0199176,
umls-concept:C0205225,
umls-concept:C0282440,
umls-concept:C0337810,
umls-concept:C0439743,
umls-concept:C0687742,
umls-concept:C1096777,
umls-concept:C1257890,
umls-concept:C2603343
|
pubmed:issue |
2
|
pubmed:dateCreated |
1996-9-10
|
pubmed:abstractText |
We randomized 220 HIV-1-infected subjects to receive aerosolized pentamidine (300 mg/4 weeks) or orally trimethoprim-sulfamethoxazole (320-1600 mg/day) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP), and evaluated PCP and toxoplasmic encephalitis (TE) occurrence and survival. Patients developing toxicity switched to the other regimen. Analysis was on intention-to-treat. At 1 year of study, we observed in the pentamidine group a non-significant excess of PCP (4 vs. 1) and TE (7 vs. 3), and a significant increased death rate (15 vs. 2). After 2 years, no significant differences were observed: adjusted RR estimates for pentamidine vs. cotrimoxazole were 1.20 (95% CI, 0.33-4.37) for PCP (6 cases vs. 5), 1.23 (95% CI, 0.46-3.29) for TE (10 vs. 8) and 1.52 (95% CI, 0.83-2.79) for death (30 vs. 18). Crossovers were more frequent in the cotrimoxazole group (41 vs. 4, P < 0.001). Aerosolized pentamidine and cotrimoxazole were equally effective in preventing PCP, and no major differences were observed in TE occurrence and survival after 2 years follow-up.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0163-4453
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
123-31
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:8708369-AIDS-Related Opportunistic Infections,
pubmed-meshheading:8708369-Adult,
pubmed-meshheading:8708369-Aerosols,
pubmed-meshheading:8708369-Female,
pubmed-meshheading:8708369-HIV-1,
pubmed-meshheading:8708369-Humans,
pubmed-meshheading:8708369-Male,
pubmed-meshheading:8708369-Pentamidine,
pubmed-meshheading:8708369-Pneumonia, Pneumocystis,
pubmed-meshheading:8708369-Toxoplasmosis, Cerebral,
pubmed-meshheading:8708369-Trimethoprim-Sulfamethoxazole Combination
|
pubmed:year |
1996
|
pubmed:articleTitle |
Risks and benefits of aerosolized pentamidine and cotrimoxazole in primary prophylaxis of Pneumocystis carinii pneumonia in HIV-1-infected patients: a two-year Italian multicentric randomized controlled trial. The Italian PCP Study Group.
|
pubmed:affiliation |
Institute of Internal Medicine, Infectious Diseases and Immunopathology, University of Milan, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|